Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

Separately, Alliance Global Partners cut their price target on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Trading Up 1.3 %

NASDAQ AWH opened at $0.76 on Monday. Aspira Women’s Health has a 12 month low of $0.67 and a 12 month high of $5.65. The stock has a market cap of $12.67 million, a price-to-earnings ratio of -0.63 and a beta of 1.44. The company’s 50 day moving average is $0.84 and its two-hundred day moving average is $1.29.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.